Correlation Between Telix Pharmaceuticals and Bank of Queensland

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Telix Pharmaceuticals and Bank of Queensland at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Telix Pharmaceuticals and Bank of Queensland into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Telix Pharmaceuticals and Bank of Queensland, you can compare the effects of market volatilities on Telix Pharmaceuticals and Bank of Queensland and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Telix Pharmaceuticals with a short position of Bank of Queensland. Check out your portfolio center. Please also check ongoing floating volatility patterns of Telix Pharmaceuticals and Bank of Queensland.

Diversification Opportunities for Telix Pharmaceuticals and Bank of Queensland

0.17
  Correlation Coefficient

Average diversification

The 3 months correlation between Telix and Bank is 0.17. Overlapping area represents the amount of risk that can be diversified away by holding Telix Pharmaceuticals and Bank of Queensland in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bank of Queensland and Telix Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Telix Pharmaceuticals are associated (or correlated) with Bank of Queensland. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bank of Queensland has no effect on the direction of Telix Pharmaceuticals i.e., Telix Pharmaceuticals and Bank of Queensland go up and down completely randomly.

Pair Corralation between Telix Pharmaceuticals and Bank of Queensland

Assuming the 90 days trading horizon Telix Pharmaceuticals is expected to generate 7.82 times more return on investment than Bank of Queensland. However, Telix Pharmaceuticals is 7.82 times more volatile than Bank of Queensland. It trades about 0.1 of its potential returns per unit of risk. Bank of Queensland is currently generating about 0.06 per unit of risk. If you would invest  675.00  in Telix Pharmaceuticals on September 16, 2024 and sell it today you would earn a total of  1,778  from holding Telix Pharmaceuticals or generate 263.41% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Telix Pharmaceuticals  vs.  Bank of Queensland

 Performance 
       Timeline  
Telix Pharmaceuticals 

Risk-Adjusted Performance

17 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Telix Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.
Bank of Queensland 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Bank of Queensland are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Bank of Queensland is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Telix Pharmaceuticals and Bank of Queensland Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Telix Pharmaceuticals and Bank of Queensland

The main advantage of trading using opposite Telix Pharmaceuticals and Bank of Queensland positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Telix Pharmaceuticals position performs unexpectedly, Bank of Queensland can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bank of Queensland will offset losses from the drop in Bank of Queensland's long position.
The idea behind Telix Pharmaceuticals and Bank of Queensland pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Complementary Tools

Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Transaction History
View history of all your transactions and understand their impact on performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments